Oncology

Patients need evidence that reflects real benefit.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

GDF15 can reshape prostate cancer prognosis and treatment; pharmacists track emerging biomarker panels and targeted therapies for metastatic disease.

H. pylori requires diagnosis, antibiotic- and acid-suppression-based therapy, and post-treatment eradication confirmation to prevent gastritis and cancer.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

Oncology pharmacists use MammaPrint to target anthracyclines in high-risk breast cancer, sparing others cardiotoxicity and severe nausea.

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.

DPYD Testing reshapes oncology dosing for 5‑FU/capecitabine to prevent toxicity and personalize chemotherapy.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

Pharmacists unpack CAR T-cell therapy in acute lymphoblastic leukemia, spotlighting obecabtagene autoleucel data and toxicity tips.

Explore how pharmacists can support patients with pancreatic cancer taking atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

Study results suggest young participants who survived cancer have difficulty in areas such as memory, attention, and ability to process information compared with those who did not have cancer.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for patients with pancreatic cancer.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

Experts discuss the role of pharmacists in CAR T-cell and gene therapy at the 2026 ASTCT Tandem Meeting in Salt Lake City.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Innovative biodegradable nanoplatforms enhance cancer therapy by integrating targeted drug delivery and real-time imaging, revolutionizing oncology practices for pharmacists.

Zavabresib receives orphan drug designation for myelofibrosis, offering hope for patients unresponsive to current treatments and enhancing therapeutic options.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.

CMS announces the selection of 15 high-cost drugs for Medicare price negotiations, aiming to reduce prescription costs for older adults and taxpayers.

FDA approves a new quadruplet therapy for newly diagnosed multiple myeloma, enhancing treatment options for patients ineligible for stem cell transplant.

FDA's draft guidance on MRD and CR as end points accelerates multiple myeloma therapy approvals, enhancing patient access and transforming oncology practices.

Innovative immunotherapy strategies, like linvoseltamab, show promise in treating multiple myeloma, potentially reducing reliance on traditional transplants.